rTMS Response Varies by Depressive Phenotype: Preclinical Insights

Distinct rTMS Effects Observed Across Depression Phenotypes

Repetitive transcranial magnetic stimulation (rTMS) produces markedly different behavioral, neuroendocrine, and molecular outcomes depending on the depressive phenotype, according to a preclinical study published on October 13, 2026 (OpenAlex W7221592036). Using male Wistar-Kyoto rats, researchers modeled treatment-resistant depression (TRD) via chronic mild stress and social isolation, and treatment-responsive depression (ISO) via social isolation alone. Non-depressed controls (CTRL) were also included. High-frequency rTMS was administered, and behavioral batteries, plasma corticosterone, and gene expression in the prefrontal cortex and hippocampus were assessed at multiple time points.

The study found that in ISO rats, rTMS led to broad behavioral improvements and normalization of basal corticosterone, a key stress hormone. In contrast, TRD rats exhibited more selective behavioral gains—primarily in motivation and self-care—without normalization of corticosterone. The most prominent molecular changes in TRD animals were increased expression of brain-derived neurotrophic factor (Bdnf) and cannabinoid receptor 1 (Cnr1) in the prefrontal cortex, with a strong positive correlation between these markers only in actively stimulated TRD rats. This suggests rTMS engages distinct adaptive mechanisms based on underlying neurobiological state.

Mechanistic Insights and Context for Neuromodulation Research

rTMS appears to recruit phenotype-specific neurobiological pathways, rather than producing a uniform antidepressant effect across all forms of depression. In treatment-responsive models, neuroendocrine normalization (as reflected by corticosterone reduction) may underpin broad behavioral recovery. In TRD models, however, behavioral improvements are linked to coordinated upregulation of Bdnf and Cnr1 in the prefrontal cortex, implicating plasticity and endocannabinoid signaling as potential mediators.

This mechanistic divergence is significant for translational research, as it highlights the risk of overgeneralizing rTMS efficacy from one depressive subtype to another. The findings also suggest that combining rTMS with interventions targeting plasticity or endocannabinoid pathways—such as certain psychedelics—could be a rational strategy for TRD, though this remains to be tested in clinical settings.

Notably, the strong correlation between Bdnf and Cnr1 expression in TRD rats receiving rTMS was not observed in other groups, indicating a possible biomarker signature for mechanism-guided treatment tailoring. This insight is rarely surfaced in clinical trial design, where patient stratification by neurobiological markers is still uncommon.

Policy and Research Implications for Personalized Treatment

The study supports a shift toward mechanism-guided, personalized neuromodulation strategies in depression treatment. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly emphasize the need for precision medicine approaches, especially in psychiatric disorders where treatment response is highly variable.

For clinical trialists and sponsors, these results underscore the importance of stratifying participants by depressive phenotype and, where possible, incorporating molecular or neuroendocrine biomarkers into study protocols. This could improve signal detection and reduce the risk of failed trials due to heterogeneity in response. The study also raises questions about the generalizability of existing rTMS protocols, which are often standardized rather than individualized.

For researchers exploring combined or comparative approaches—such as rTMS plus psychedelic-assisted therapy—this work provides a mechanistic rationale for targeting specific neurobiological pathways in TRD, rather than relying solely on symptomatic criteria.

Risks, Unknowns, and Translational Challenges

Preclinical findings do not always translate directly to human populations, and the rodent models used—while well-validated—cannot capture the full complexity of human depression. The study’s reliance on male rats also limits generalizability across sexes. Moreover, the molecular markers identified (Bdnf and Cnr1) are not currently used in routine clinical practice, and their utility as treatment biomarkers in humans remains to be established.

Another risk is that mechanism-guided approaches could inadvertently exclude patients who do not fit neatly into defined phenotypes, potentially limiting access to care. There is also uncertainty about the long-term effects and safety of targeting plasticity and endocannabinoid pathways, particularly when considering combination therapies.

Finally, while rTMS is generally well-tolerated, its efficacy in TRD remains modest, and the field must guard against overinterpreting preclinical mechanistic findings as evidence of clinical benefit.

Future Directions and Clinical Translation

Personalized neuromodulation for depression will likely require integration of behavioral, endocrine, and molecular profiling to optimize treatment selection. Future clinical trials should consider including biomarker-driven stratification, longitudinal monitoring of neuroendocrine and plasticity markers, and exploration of combined rTMS and psychedelic protocols in TRD populations.

As agencies and funders increasingly demand precision in psychiatric intervention, the field will need to develop scalable, accessible tools for phenotype and biomarker assessment. This study provides a mechanistic foundation for such efforts, but clinical validation and regulatory acceptance remain key hurdles.

Reviewed by Dr. Alex M. Carter, PhD (Neuroscience), on 2026-10-15. Research based on primary source: OpenAlex W7221592036.